Ilkka Oyj
13.3.2026 18:00:00 CET | Globenewswire | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
Ilkka Oyj: Acquisition of own shares on 13 March 2026
Ilkka Oyj Stock Exchange Release 13 March 2026, at 07:00 p.m. EET
Ilkka Oyj: Acquisition of own shares on 13 March 2026
| Date | 13 March 2026 | |
| Exchange transaction | Buy | |
| Share trading code | ILKKA2 | |
| Amount, shares | 3,000 | |
| Average price/share (EUR) | 4.2385 | |
| Total cost (EUR) | 12,715.50 |
After the acquisitions Ilkka Oyj holds a total of 124,071 treasury shares (ILKKA2).
On behalf of Ilkka Oyj
Danske Bank A/S, Finland Branch
Antti Väliaho Jonathan Nyberg
For more information, please contact:
Olli Pirhonen, CEO, Ilkka Oyj
olli.pirhonen@ilkka.com
DISTRIBUTION
Nasdaq Helsinki
Main media
www.ilkka.com
Ilkka Oyj in brief
Ilkka is a marketing and technology company that offers professional, data and technology services in digital marketing and communications. The core of Ilkka's business is formed by the software company Liana, a pioneer in marketing and communication technology, and its Swedish subsidiary Ungapped; the leading expert in data-driven sales and marketing, Profinder; Finland's leading WordPress digital agency Evermade; Finland's leading social media marketing expert agency MySome; and the strategic B2B marketing partner Myynninmaailma. Our success relies heavily on knowing the entire purchase path and utilizing modern technology, data, and AI. Our international focus is particularly on Sweden and the emerging markets in the Middle East. The group's services are provided by approximately 330 marketing, technology, and data experts.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Lassila & Tikanoja Plc13.3.2026 17:30:00 CET | Press release
Lassila & Tikanoja Plc: Share Repurchase 13.3.2026
Sanoma Corp13.3.2026 17:30:00 CET | Press release
SANOMA CORPORATION: ACQUISITION OF OWN SHARES 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom